Skip to main content

Table 1 Characteristics of included studies

From: Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs

Study Participants, n RA type Intervention Duration Outcomes
Xia 2016 150 Active RA IGU+MTX vs. IGU vs. MTX 24 weeks ACR20, ACR50, ACR70, DAS28-ESR, DAS28-CRP, duration of morning stiffness, HAQ, adverse events.
Zhao 2017 96 Active RA IGU+MTX vs. IGU vs. MTX 24 weeks ACR20, ACR50, ACR70, DAS28-CRP, HAQ, adverse events.
Cao 2018 90 Active RA IGU+MTX vs. IGU vs. MTX 24 weeks DAS28-CRP, HAQ
Xu 2015 110 Active RA IGU+MTX vs. IGU vs. MTX 52 weeks Duration of morning stiffness, adverse events.
Zhao 2016 90 Active RA IGU+MTX vs. IGU vs. MTX 24 weeks ACR20, ACR50, ACR70, adverse events.
Xiong 2015 86 Active RA IGU+MTX vs.IGU vs. MTX 24 weeks DAS28-ESR, adverse events.
Lv 2014 131 Active RA IGU+MTX vs. IGU vs. MTX 24 weeks DAS28-ESR, DAS28-CRP, duration of morning stiffness, HAQ
Duan 2015 60 Active RA IGU+MTX vs. MTX 24 weeks ACR20, ACR50, ACR70, DAS28, HAQ, adverse events.
Ishiguro 2013 252 Active RA IGU+MTX vs. MTX 24 weeks ACR20, ACR50, ACR70, HAQ, adverse events.
Ren 2017 82 Active RA IGU+MTX vs. MTX 26 weeks Duration of morning stiffness, adverse events.
Wang 2017 120 Active RA IGU+MTX vs. MTX 68 weeks DAS28-ESR, adverse events.
Bai 2015 100 Active RA IGU+MTX vs. MTX 24 weeks ACR20, ACR50, adverse events.
Xie 2018 120 Refractory RA IGU+MTX vs. MTX 17 weeks DAS28-ESR, adverse events.
Wang 2016 87 Refractory RA IGU+MTX vs. MTX 24 weeks DAS28, adverse events.
Meng 2016 60 Refractory RA IGU+MTX vs. MTX 16 weeks DAS28-ESR, adverse events.
Chen 2018 120 Active RA IGU+MTX vs. MTX 24 weeks Duration of morning stiffness, adverse events.
Xu 2017 83 Active RA IGU+MTX vs. MTX 52 weeks DAS28, adverse events.
Xiong 2020 102 Active RA IGU+MTX vs. MTX 24 weeks Duration of morning stiffness, adverse events.
Lu 2009 326 Active RA IGU vs. MTX 24 weeks ACR20, ACR50, ACR70, duration of morning stiffness, HAQ, adverse events.
Yang 2017 60 Active RA IGU vs. MTX 12 weeks DAS28-ESR, duration of morning stiffness.
Hu 2014 40 Active RA IGU vs. MTX 24 weeks ACR20, DAS28-ESR, adverse events.
Dai 2019 108 Active RA IGU+Leflunomide vs. Leflunomide 12 weeks DAS28-3, duration of morning stiffness, adverse events.
Li 2018 60 Refractory RA IGU+ Etanercept vs. Etanercept 12 weeks DAS28-ESR, adverse events.